Floatz logo

Carboplatin

Recurrent Mucoepidermoid Carcinoma of the Oral Cavity

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Recurrent Mucoepidermoid Carcinoma of the Oral Cavity cohort.

Asset / SponsorPhaseRating
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Irinotecan
National Cancer Institute (NCI)
Phase 1/2B
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC
Alvespimycin
National Cancer Institute (NCI)
Phase 1CC

View all 11 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →